By IANS
Mumbai : Indian pharma major Glenmark Pharmaceuticals Ltd has started marketing its drugs for skin disorders in the US.
Informing the Bombay Stock Exchange (BSE) about this Monday, the company said the marketing was being done by its US-based wholly owned subsidiary Glenmark Pharmaceutical Inc (GPI).
The company had acquired marketing rights after a green signal from the US Food and Drugs Administration (USFDA) for a line of Clobetasol Propionate products in the form of cream, ointment, gel and topical solutions.
According to the company, the generic Clobetasol Propionate is administered as external application in the treatment of skin diseases like eczema and psoriasis.
The company also plans an entry into the US semisolid product market and is studying the launch of an additional 11 dermatological products in one year’s time.
The number of GPI’s generic products in the US market now touches 28. In the coming months the company is expecting more forays into the US market as at present it has over 35 abbreviated new drug applications awaiting USFDA launch approval.